Tactical Therapeutics, Inc., Selected to Present at Cavendish Global Health Impact Forum

Forum uniquely brings together leading family offices and their foundations seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences

New York, April 2, 2015, — Tactical Therapeutics, Inc., a clinical stage oncology drug development company, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place May 10th to May 14th in La Jolla, California. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission, the Forum showcases presentations and panel discussions by leading research institutions, accomplished healthcare delivery professionals, health-policy experts and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis, and treatment. Cavendish Impact Forums are hosted by leading institutions around the world and take place three times each year. The May 2015 Forum is being co-hosted by the community of La Jolla, California including the University of California San Diego, the J. Craig Venter Institute, the Scripps Research Institute, the Sanford-Burnham Medical Research Institute, the Sanford Consortium for Regenerative Medicine, and the Institute of the Americas.

Michael Moffat, Cavendish co-founder and Chief Executive Officer explains, "The theme of our La Jolla, California Forum is a 'Celebration of Philanthropy, Impact Investing and Innovation that is Changing the World.' With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of Tactical Therapeutics' research and scientific insights in glioblastoma positions them to make a major contribution to the treatment and management of this orphan indication, glioblastoma, for which there is an unmet need because of lack of effective treatments."

"We are honored to be selected to present at this unique event, and it is further recognition of our innovative approach to treat and manage newly diagnosed and recurrent glioblastoma and other malignant gliomas afflicting populations around the world today," said Rashida Karmali, Ph.D, CEO at Tactical Therapeutics**.** "We welcome the chance to interact with many of world's most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world."

Cavendish Global consists of leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship-building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making, and impact investing. The Forum is

also an opportunity for family offices to champion and share information on projects and organizations which they are passionate about with other family offices from around the world.

About Tactical Therapeutics, Inc

Tactical Therapeutics, Inc., is a clinical stage company that has developed and patented a lead therapeutic Carboxyamidotriazole Orotate (CTO) for the orphan indication glioblastoma (GBM) and malignant glioma. CTO is a novel oral inhibitor of calcium signal transduction with demonstrated activity against multiple tyrosine kinase pathways that are active onco-drivers in glioblastoma. CTO is currently in multiple Phase I/II trials for GBM with several leading cancer research institutions including Memorial Sloan-Kettering Cancer Center, Duke Cancer Center, and New York University Brain Tumor Center. In a study on recurrent refractory GBMs and gliomas, CTO given orally in combination with Temodar® showed a safe toxicity profile. Durable stable disease and partial responses are confirmed in both methylated and unmethylated MGMT GBM tumors. These results suggest that CTO synergizes with and induces chemosensitivity to Temodar® without crippling neurotoxicities. Studies in newly diagnosed GBM are underway. Tactical Therapeutics is seeking a strategic partner to participate in the development and commercialization of the company's lead product, CTO.

Further information is available on the Company's website, www.tacticaltherapeutics.com. Contact
For Further Information Contact:

Rashida Karmali, CEO, Tactical Therapeutics
rashida@tacticaltherapeutics.com
Tel: +1-917-763-7196

About Cavendish Global
Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship-building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, including Cavendish Impact Forums. A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; the next Forum is being co-hosted at leading research institutions of the community of La Jolla, California including the University of California San Diego, the J. Craig Venter Institute, the Scripps Research Institute, the Sanford-Burnham Medical Research Institute, the Sanford Consortium for Regenerative Medicine, and the Institute of the Americas.

For more information: http://cavendishglobal.com
For Further Information Contact:

Alex Charlton
President, Cavendish Global
alex.charlton@cavendishglobal.com
Tel: +1-917-576-1435